Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 6/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.36 |
| ▸ | IFNAR1 | P17181 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NPY1R | P25929 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NPY2R | P49146 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4824600 | 1.00 | SLC6A4 (0.52) | SLC6A4SLC6A3SLC6A2HTR1ASLC18A2 | |
| SCHEMBL3423701 | 0.82 | SLC6A3 (0.66) | SLC6A4SLC6A3SLC6A2HTR1AHTR6 | |
| SCHEMBL6743669 | 0.74 | SLC6A4 (0.58) | SLC6A4SLC6A3SLC6A2HTR1AHTR6 | |
| SCHEMBL4822755 | 0.71 | SLC6A4 (0.48) | SLC6A4SLC6A3SLC6A2SLC18A2IFNAR1 | |
| SCHEMBL4904964 | 0.70 | HTR6 (0.46) | SLC6A4HTR1AALDH1A1LMNANPY1R | |
| SCHEMBL8207336 | 0.70 | SLC6A4 (0.71) | SLC6A4SLC6A3SLC6A2HTR1AHTR6 | |
| SCHEMBL4813544 | 0.69 | HPGD (0.38) | IFNAR1ALDH1A1LMNANPY1RMAPK1 | |
| SCHEMBL1020818 | 0.69 | SLC6A2 (0.69) | SLC6A4SLC6A3SLC6A2HTR1ALMNA | |
| SCHEMBL5829683 | 0.69 | SLC6A4 (0.69) | SLC6A4SLC6A3SLC6A2HTR1ALMNA | |
| SCHEMBL2889995 | 0.68 | SLC6A4 (0.63) | SLC6A4SLC6A3SLC6A2HTR1AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-7375125-B2 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375125-B2 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375125-B2 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-6699873-B1 | EATING DISORDERS | MILLENNIUM PHARMACEUTICALS, INC. | 2004-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MC4R, MC5R, MC3R | SLC6A4 137/4885SLC6A3 376/4885SLC6A2 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.